Faron Pharmaceuticals (AIM: FARN; First North: FARON) has announced the publication of a comprehensive review article in the peer-reviewed journal Immunotherapy detailing the potential of the company’s lead candidate, bexmarilimab, to overcome immune resistance in cancer.
The article, titled Clinical optimization of bexmarilimab as a myeloid checkpoint therapy, outlines how inhibition of Clever-1—a scavenger receptor expressed on immunosuppressive macrophages—using bexmarilimab could become a cornerstone of next-generation, multi-indication cancer immunotherapy.
In a statement, Dr. Maija Hollmén, senior author and CSO of Faron, and Adjunct Professor of Tumour Immunology, Group Leader, MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland, commented, “This peer-reviewed publication is the culmination of our deep-rooted scientific understanding of the myeloid cell’s role in cancer. By highlighting how bexmarilimab specifically reprograms Clever-1-positive macrophages from a pro-tumoral to a pro-inflammatory state, we are demonstrating that the immune system can be re-ignited. This review clarifies that targeting myeloid checkpoints is not just a secondary strategy, but a primary requirement for overcoming the immunosuppressive microenvironment that current therapies often fail to penetrate.”
